4,361
Participants
Start Date
September 9, 2021
Primary Completion Date
September 17, 2021
Study Completion Date
September 17, 2021
High Efficacy Therapy (HET)
HET include alemtuzumab, ofatumumab, ocrelizumab, natalizumab, cladribine, fingolimod and ozanimod.
Non High Efficacy Therapy (Non-HET)
Non-HETs include molecules classified as with moderate or modest efficacy such as: interferons, glatiramer acetate, dimethyl fumarate and teriflunomide.
Novartis Investigative Site, East Hanover
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY